Prosecution Insights
Last updated: April 19, 2026
Application No. 18/018,885

MULTI-EFFICACY PYRAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF

Non-Final OA §112
Filed
Aug 25, 2023
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Olive Biopharmaceuticals Co. Ltd.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
900 granted / 1477 resolved
+0.9% vs TC avg
Strong +44% interview lift
Without
With
+43.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
47 currently pending
Career history
1524
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1477 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application, filed 08/25/2023 is a National Stage entry of PCT/CN2021/109563, International Filing Date: 07/30/2021. PCT/CN2021/109563 claims foreign priority to 202010759391.0, filed 07/31/2020; and claims foreign priority to 202010759395.9, filed 07/31/2020. Certified copies of the foreign priority applications are of record. Status of Claims Claims 1-21 are currently pending. Claims 1-21 were examined. Claims 2-3 and 9 are rejected. Claims 1, 4-8, and 10-21 are allowed. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2 and 9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 depends directly from claim 1 and recites the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, alkoxy, alkylcarboxyl, alkylester, alkyl-OH, alkylamino, -alkyl-NH2, aryl, heteroaryl, carbonate, carbamate, -alkyl-acylamino, and aminocarbonate groups to be optionally substituted. However, other than being optionally deuterated, claim 1 doesn’t recite the above groups to be alternatively substituted with other groups. There is insufficient antecedent basis for these limitations in the claim, and the claim is indefinite. Claim 9 is drawn to a process of preparing a compound but appears to be missing some vital steps: PNG media_image1.png 200 400 media_image1.png Greyscale . There are two arrows shown above indicating transformations to arrive at the final compound, however, the specific steps, e.g., reagents and/or reaction conditions are not provided. The metes and bounds of the claim aren’t clear, and the claim is indefinite. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 depends directly from claim 1 and recites “wherein n is 0, 1, 2, 3, 4, 5, or 6; and m is 0, 1, 2, 3, 4, or 5”. However, these limitations are already present in claim 1, and the claim therefore doesn’t further limit claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: the compounds of formula I are not taught or suggested by the prior art. Wang et. al., CN 105294666 A, publ. 2/3/2016, cited in an IDS, represents the most relevant prior art. Wang teaches pyrazine compounds that are bound via a linker to a phenyl ring. However, the compounds taught by Wang don’t have the linking group required by formula I of the instant claims: PNG media_image2.png 200 400 media_image2.png Greyscale . Wang doesn’t teach or suggest modifications to arrive at the claimed compounds. Information Disclosure Statement The IDS filed on 1/19/24 has been considered. Correspondence Claims 1-21 were examined. Claims 2-3 and 9 are rejected. Claims 1, 4-8, and 10-21 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Aug 25, 2023
Application Filed
Nov 26, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599584
INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594236
Method of Treating Acute Exacerbation of Schizophrenia with Long-Acting Injectable Depot Composition
2y 5m to grant Granted Apr 07, 2026
Patent 12594338
CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12576047
TELOMERASE ACTIVATING COMPOUNDS FOR USE IN FERTILITY AND RELATED APPLICATIONS
2y 5m to grant Granted Mar 17, 2026
Patent 12577209
AMINO ACID COMPOSITIONS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+43.7%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1477 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month